DFF332 Elicits Efficacy and Is Safe in Advanced Clear Cell R

The small molecule inhibitor DFF332 elicited clinical activity and had a tolerable safety profile in patients with advanced clear cell renal cell carcinoma.

Related Keywords

California , United States , Sumanta Kumar Pal , Bladder Cancer Disease Team , Kidney Cancer Program , Database Consortium , International Metastatic , Medical Oncology , Therapeutics Research , Hope Comprehensive Cancer Center ,